Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement

Ophthalmology

Volumn 106, Issue 10, 1999, Pages 1900-1907

  Hassan, Adam S ^a   Johnson, Mark W ^a,f   Schneiderman, Todd E ^b   Regillo, Carl D ^c   Tornambe, Paul E ^d   Poliner, Lon S ^d   Blodi, Barbara A ^e   Elner, Susan G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Pacific Eye Care   (United States)

^c WILLS EYE HOSPITAL   (United States)

^d Retina Consultants   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; FLUOROCARBON; OCTAFLUOROPROPANE; SULFUR HEXAFLUORIDE; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ANEURYSM; ARTICLE; BODY POSTURE; CLINICAL TRIAL; EYE INJURY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INJECTION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; POSTOPERATIVE COMPLICATION; RETINA BLOOD VESSEL; RETINA HEMORRHAGE; RETINA MACULA DEGENERATION; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEURYSM; EYE INJURIES; FEMALE; FIBRINOLYTIC AGENTS; FLUOROCARBONS; HUMANS; INJECTIONS; MACULA LUTEA; MACULAR DEGENERATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRONE POSITION; RETINAL HEMORRHAGE; RETINAL VESSELS; RETROSPECTIVE STUDIES; SULFUR HEXAFLUORIDE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 0033208857     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)90399-8     Document Type: Article

References (27)

1. Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990;109:33-7.
2. Berrocal MH, Lewis ML, Flynn HW Jr. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol 1996;122:486-93.
3. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996;16:183-9.
4. Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol 1997;42:195-213.
5. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982;94:762-73.
6. Toth CA, Morse LS, Hjelmeland LM, Landers MB III. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991;109:723-9.
7. Johnson MW, Olsen KR, Hernandez E. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Retina 1991;11:250-8.
8. Benner JD, Morse LS, Toth CA, et al. Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. Arch Ophthalmol 1991;109:1731-6.
9. Boone DE, Boldt HC, Ross RD, et al. The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model. Retina 1996;16:518-24.
10. Coll GE, Sparrow JR, Marinovic A, Chang S. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995;15:319-26.
11. Johnson MW, Olsen KR, Hernandez E. Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage. Ophthalmology 1992;99:515-21.
12. Lewis H, Resnick SC, Flannery JG, Straatsma BR. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol 1991;111:197-204.
13. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994;118:559-68.
14. Ibanez HE, Williams DF, Thomas MA, et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol 1995;113:62-9.
15. Lim JI, Drews-Botsch C, Sternberg P Jr, et al. Submacular hemorrhage removal. Ophthalmology 1995;102:1393-9.
16. Moriarty AP, McAllister IL, Constable IJ. Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage. Eye 1995;9:582-8.
17. Kamei M, Tano Y, Maeno T, et al. Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol 1996;121:267-75.
18. Hesse L, Meitinger D, Schmidt J. Little effect of tissue plasminogen activator in subretinal surgery for acute hemorrhage in age-related macular degeneration. Ger J Ophthalmol 1997; 5:479-83.
19. Claes C, Zivojnovic R. Efficacy of tissue plasminogen activator (t-PA) in subretinal hemorrhage removal. Bull Soc Belge Ophtalmol 1996;261:115-8.
20. el Baba F, Jarrett WH II, Harbin TS Jr, et al. Massive hemorrhage complicating age-related macular degeneration. Clinicopathologic correlation and role of anticoagulants. Ophthalmology 1986;93:1581-92.
21. Koshibu A, Kaga N, Ohkuma H, et al. Ultrastructural studies on the absorption of experimentally produced subretinal hemorrhage [in Japanese] [Eng. abstr]. Folia Ophthalmologica Japonica 1978;29:20-7.
22. Sternberg P Jr, Aguilar HE, Drews C, Aaberg TM. The effect of tissue plasminogen activator on retinal bleeding. Arch Ophthalmol 1990;108:720-2.
23. Takeuchi A, Kricorian G, Yao XY, et al. The rate and source of albumin entry into saline-filled experimental retinal detachments. Invest Ophthalmol Vis Sci 1994;35:3792-8.
24. Johnson MW, Olsen KR, Hernandez E, et al. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990;108:259-63.
25. Zemel E, Loewenstein A, Lei B, et al. Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity. Invest Ophthalmol Vis Sci 1995;36:1875-84.
26. Ohji M, Saito Y, Hayashi A, et al. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998;116:1326-32.
27. Kimura AE, Reddy CV, Folk JC, Farmer SG. Removal of subretinal hemorrhage facilitated by preoperative intravitreal tissue plasminogen activator [letter]. Retina 1994;14:83-4.